Drugs / BIM23B065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03045302 | Jan → May 2017 | acromegaly | Ipsen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIM23B065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03045302 ↗ |
| Route | Subcutaneous | “Subcutaneous twice a day or three times a day administration of BIM23B065.” NCT03045302 ↗ |